Researchers from Aston University and the Royal Orthopaedic Hospital (ROH) are pioneering an innovative injectable paste designed to treat both primary and metastatic bone cancers. This groundbreaking approach combines gallium, a metal with known anticancer properties, and bioactive glass, which supports bone regeneration. The resulting gallium-doped bioglass has demonstrated a remarkable 99% success rate in laboratory settings for eliminating cancerous cells while simultaneously promoting new bone growth.

The development of this injectable paste addresses significant challenges in bone cancer treatment, particularly when complete surgical removal of tumors is not feasible. Such scenarios often arise when tumors are located near vital organs or when aggressive surgery poses substantial risks to the patient. By delivering anticancer gallium ions directly to the affected area, the paste aims to reduce cancer recurrence, prevent infections, and enhance bone healing. This minimally invasive approach holds promise for improving outcomes in patients with bone metastases originating from various cancers.

The injectable paste not only targets residual cancer cells but also fosters bone regeneration, offering a comprehensive solution to the challenges posed by bone tumors and metastases.

Source.